Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Johnson
K P
KP
Brooks
B R
BR
Cohen
J A
JA
Ford
C C
CC
Goldstein
J
J
Lisak
R P
RP
Myers
L W
LW
Panitch
H S
HS
Rose
J W
JW
Schiffer
R B
RB
Vollmer
T
T
Weiner
L P
LP
Wolinsky
J S
JS
D017326:Clinical Trials, Phase III as Topic / Q000266:history; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D049673:History, 20th Century; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic / Q000266:history; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000266:history*; D010455:Peptides / Q000266:history* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000266:history
D010455:Peptides; D000068717:Glatiramer Acetate